Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
…, W Zoli, P Ulivi, G Gallerani, P Fici, E Chiadini… - Cancer letters, 2013 - Elsevier
The characterization of circulating tumor cells (CTCs) could substantially improve the
management of cancer patients. However, their study is still a matter of debate, often due to …
management of cancer patients. However, their study is still a matter of debate, often due to …
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
M Canale, E Petracci, A Delmonte, E Chiadini… - Clinical Cancer …, 2017 - AACR
Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). …
inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). …
[HTML][HTML] Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation
…, W Zoli, L Capelli, E Chiadini… - Molecular and …, 2013 - spandidos-publications.com
In recent years, a number of new agents that target specific molecular pathways in non-small
cell lung cancer (NSCLC) have been investigated. Much effort has been focused on …
cell lung cancer (NSCLC) have been investigated. Much effort has been focused on …
Nonsquamous, non-small-cell lung cancer patients who carry a double mutation of EGFR, EML4-ALK or KRAS: frequency, clinical-pathological characteristics, and …
P Ulivi, E Chiadini, C Dazzi, A Dubini, M Costantini… - Clinical lung cancer, 2016 - Elsevier
Background Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-…
viral oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-…
[HTML][HTML] Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
…, E Petracci, A Delmonte, G Bronte, E Chiadini… - Journal of clinical …, 2020 - mdpi.com
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related
deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit …
deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit …
[HTML][HTML] Right-vs. left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacy
P Ulivi, E Scarpi, E Chiadini, G Marisi… - International journal of …, 2017 - mdpi.com
There is evidence of a different response to treatment with regard to the primary tumor
localization (right-sided or left-sided) in patients with metastatic colorectal cancer (mCRC). We …
localization (right-sided or left-sided) in patients with metastatic colorectal cancer (mCRC). We …
[HTML][HTML] Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study
…, M Valgiusti, W Zoli, E Scarpi, E Chiadini… - Journal of Translational …, 2012 - Springer
Background KRAS mutations negatively affect outcome after treatment with cetuximab in
metastatic colorectal cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients …
metastatic colorectal cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients …
[HTML][HTML] Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a …
A Casadei Gardini, E Chiadini, L Faloppi, G Marisi… - BMC cancer, 2016 - Springer
Background Sorafenib is a multi-targeted kinase inhibitor with a demonstrated activity in renal
cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the …
cell carcinoma (RCC) and hepatocellular carcinoma (HCC), and it is currently used for the …
[HTML][HTML] Liquid biopsy for EGFR mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience
…, M Canale, I Priano, L Capelli, D Calistri, E Chiadini… - Biomedicines, 2021 - mdpi.com
Background: Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from
NSCLC patients has become routine. The aim of this study was to explore its applicability in …
NSCLC patients has become routine. The aim of this study was to explore its applicability in …
Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer …
P Ulivi, M Romagnoli, E Chiadini… - International …, 2012 - spandidos-publications.com
In non-small cell lung cancer (NSCLC) patients, somatic EGFR and K-ras mutations predict
therapeutic effectiveness and resistance, respectively, to EGFR tyrosine kinase inhibitors (…
therapeutic effectiveness and resistance, respectively, to EGFR tyrosine kinase inhibitors (…